FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer January 15th 2024January 15th 2024 Read More
OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer January 15th 2024January 15th 2024 Read More
Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer January 15th 2024January 15th 2024 Read More
Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer January 29th 2024January 12th 2024 Read More
Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology October 24th 2023 Read More